3Renwick W, Pettengell R, Green M. Use. of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience [J].BioDrugs, 2009, 23 ( 3 ) : 175-186. DOI : 10.2165/ 00063030-200923030 -00004.
4Shi YK, Chen Q, Zhu YZ, et ',d. Pegylated filgrasfim is comparable with filgrastim as support for commonly used chemotherapy regimens: a nmlticenter, randomized, crossover phase 3 study [J]. Anticancer Drugs, 2013, 24(6) :641-647. DOI: 10.1097/ CAD.0b013e3283610b5d.
5Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia[ J]. Ann Intern Med, 1966, 64(2) :328-340.
6Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in tile prevention and treatment of febrile neutropenia [J]. Crit Rev Oneol Hematol, 2004, 50(2) :129-146.
7Holmes FA, Jones SE, O'Shaughnessy J, et al. Compm'able efficacyand safety profiles of once-per-cycle pegfilgrastim and dai|y injection fi|grastim in chemotherapy-induced neutropenia: a muhicenter dose-finding study in women with breast cancer [ J ]. Ann Oncol, 2002, 13(6) :903-909.
8Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randonfized, muhicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage for stage ~I/1V breast cancer[ J ]. J Clin Oncol, 2002, 20(3) :727-731.
9Green MD, Koelbl H, Baselga J, et al. A randomized double- blind muhicenter phase m study of fixed-dose single- administration pegfilgrastim versus daily filgrastim in patients reeeiving myelosuppressive chemotherapy[ J ]. Ann Oncol, 2003, 14( 1 ) :29-35.
10Morrison VA, Wang M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices [ J ]. J Manag Care Pharm, 2007, 13(4) :337-348.
